| Dr Kelly Davis Loignon, PHARMD | |
|
31 Sims St, Whitmire, SC 29178-1538 | |
| (864) 346-2625 | |
| Not Available |
| Full Name | Dr Kelly Davis Loignon |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 31 Sims St, Whitmire, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386110930 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 37979 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kelly Davis Loignon, PHARMD 31 Sims St, Whitmire, SC 29178-1538 Ph: (864) 346-2625 | Dr Kelly Davis Loignon, PHARMD 31 Sims St, Whitmire, SC 29178-1538 Ph: (864) 346-2625 |
News Archive
The single largest research project ever to be undertaken by the European Society of Cardiology (ESC), EUROACTION, showed that a multidisciplinary, family based and nurse coordinated programme made a real difference in improving lifestyle and reducing cardiovascular risk among coronary patients and people with a high risk of developing Cardiovascular Disease (CVD).
The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the "Company"), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement") with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.
A study of almost 1,500 kidney cancer patients treated at Memorial Sloan Kettering Cancer Center suggests that surgery to spare as much kidney tissue as possible may improve overall survival in patients who also have reduced kidney function at the time their cancer is diagnosed. The finding is significant because both kidney cancer and decreased kidney function appear to be increasing.
› Verified 2 days ago
Blake Roche, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 68 Main St, Whitmire, SC 29178 Phone: 803-694-2445 Fax: 803-694-2013 |